KRAS and colorectal carcinoma: KYA1797K dose-dependently inhibited the growth of various CRC cells regardless of their KRAS mutational status (Fig. 3a), while the growth of CCD18-Co, normal colon cell, was mildly affected by KYA1797K treatment (Supplementary Figure S3).